AndrewDSeidmanMD

Professor, Medicine, Weill Cornell Medical College

Overview of Dr. Seidman

Dr. Andrew Seidman is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Drexel University College of Medicine/Hahnemann University and has been in practice 37 years. Dr. Seidman accepts several types of health insurance, listed below. He is one of 493 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
300 East 66th Street
Floors 1 - 4
New York, NY 10065
Book by Phone+1(646) 783-1414

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 1985 - 1988
Drexel University College of MedicineClass of 1985

Certifications & Licensure

NY State Medical License 1989 - 2026
NJ State Medical License 2020 - 2025
FL State Medical License 2019 - 2021
PA State Medical License 1986 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic Start of enrollment: 1998 Jul 01
Completed
Phase 3
Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer Start of enrollment: 1998 Apr 01
Completed
Phase 2
Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 Start of enrollment: 2000 Jan 01
Completed
Phase 2
Edotecarin in Treating Women With Locally Advanced or Metastatic Breast Cancer That Has Not Responded to Chemotherapy Start of enrollment: 2003 Jun 01
Completed
Phase 2
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 2
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer Start of enrollment: 2006 Feb 01
Terminated
Phase 2
Tesetaxel as First-line Therapy for Metastatic Breast Cancer Start of enrollment: 2010 Nov 01
Unknown status
Phase 2
Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2012 May 01
Unknown status
Phase 2
18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain Start of enrollment: 2012 Jun 13
Completed
Not Applicable
Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM) Start of enrollment: 2012 Nov 05
Completed
Phase 1
Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases Start of enrollment: 2016 Jan 06
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

210 citations
Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk
Ting Bao, Coby Basal, Christina Seluzicki, Susan Q. Li, Andrew D. Seidman
Breast Cancer Research and Treatment. 2016-08-10
22 citations
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2− metastatic breast cancer
Gebra Cuyun Carter, Kristin M Sheffield, Anala Gossai, Yu-Jing Huang, Yajun Emily Zhu
Current Medical Research and Opinion. 2021-05-20
1078 citations
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Andrew D. Seidman, Clifford A. Hudis, Mary Kathryn Pierri, Steven Shak, Virginia E. Paton
Journal of Clinical Oncology. 2002-03-01

Authored Content

A Phase IIA Trial of Acupuncture to Reduce Chemotherapy-Induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer PatientsAugust 2018

Press Mentions

Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)December 11th, 2020
Odonate Therapeutics Announces Positive Top-Line Results from CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast CancerAugust 24th, 2020
Selected Abstracts from the San Antonio Breast Cancer SymposiumFebruary 11th, 2019
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
Blue Shield California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PHCS PPO - Kaiser
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref
Please verify your coverage with the provider's office directly when scheduling an appointment